Skip to Content

Necitumumab Dosage

Applies to the following strengths: 16 mg/mL

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Non-Small Cell Lung Cancer

800 mg IV over 60 minutes on Days 1 and 8 of each 3 week cycle prior to gemcitabine and cisplatin infusion

Duration of therapy: Continue until disease progression or unacceptable toxicity

-For patients who have experienced a previous Grade 1 or 2 infusion-related reaction (IRR), premedicate with diphenhydramine (or equivalent) prior to all infusions of this drug.
-For patients who have experienced a second Grade 1 or 2 occurrence of IRR, premedicate for all subsequent infusions, with diphenhydramine (or equivalent), acetaminophen (or equivalent), and dexamethasone (or equivalent) prior to each infusion of this drug.

Use: This drug is indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


-Cardiopulmonary arrest and/or sudden death occurred in 3% of patients treated with this drug in combination with gemcitabine and cisplatin. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after administration of this drug.
-Hypomagnesemia occurred in 83% of patients receiving this drug in combination with gemcitabine and cisplatin, and was severe in 20% of patients. Monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of this drug during treatment and for at least 8 weeks following completion of or treatment. Withhold this drug for Grade 3 or 4 electrolyte abnormalities. Replete electrolytes as medically appropriate.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

-This drug is not indicated for treatment of non-squamous non-small cell lung cancer.

Reconstitution/preparation advice:
-The manufacturer product information should be consulted.

Storage requirements:
-Store under refrigeration at 2C to 8C (36F to 46F).
-Protect from light by storing in the original package until time of use.
-Do not freeze or shake.